Trial Profile
A Phase II Study of PDGFR Kinase Inhibitor in Biomarker-Enriched Recurrent Malignant Gliomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Therapeutic Use
- 13 Apr 2020 Status changed from discontinued to completed.
- 29 Oct 2018 Status changed from recruiting to discontinued.
- 06 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2018.